Treatment of Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
Open Access
- 1 January 2005
- journal article
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2005 (1) , 118-122
- https://doi.org/10.1182/asheducation-2005.1.118
Abstract
Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) includes at least one-quarter of all adults with ALL. Until recently, conventional chemotherapy programs that have been effective in other precursor B-cell ALL cases have been unable to cure patients with this diagnosis. Allogeneic stem cell transplantation early in first remission has been the recommended therapy. The availability of imatinib mesylate and other tyrosine kinase inhibitors and small molecules that affect the BCR/ABL signaling pathways may be changing the treatment paradigm and the prognosis for these patients. The results from clinical trials using imatinib in the frontline setting and in relapsed patients as well as preliminary experience treating imatinib-resistant Ph+ ALL will be described.Keywords
This publication has 32 references indexed in Scilit:
- The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemiaBlood, 2005
- Overriding Imatinib Resistance with a Novel ABL Kinase InhibitorScience, 2004
- Mechanisms of Resistance to STI571 (Imatinib) in Philadelphia-chromosome Positive Acute Lymphoblastic LeukemiaLeukemia & Lymphoma, 2004
- Early prediction of response in patients with relapsed or refractory Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinibBlood, 2004
- Efficacy and safety of imatinib mesylate (Glivec™) in combination with interferon-α (IFN-α) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)Leukemia, 2003
- Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemiaBlood, 2003
- Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)Leukemia, 2002
- Efficacy of imatinib mesylate (STI571) in conjunction with alpha-interferon: long-term quantitative molecular remission in relapsed P-190BCR-ABL-positive acute lymphoblastic leukemiaLeukemia, 2002
- A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemiasBlood, 2002
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeNew England Journal of Medicine, 2001